SuperGen ceo joins BIO board

James Manuso joins the US-based biotechnology organisation

James Manuso, chief executive of SuperGen, a US developer of novel cancer therapies, has been elected to the board of the Biotechnology Industry Organization (BIO), based in Washington, DC.

BIO’s board includes members of the governing boards for each of the organisation’s four sections: health, emerging companies, industrial and environmental and food and agriculture. Manuso has joined BIO’s health section governing board.

In addition, Manuso will serve on the BIO board Standing Committee on International Affairs.

SuperGen has been a member of BIO since 2003.

Manuso has been SuperGen chairman, president and chief executive since January 2004. He is co-founder and immediate past president and chief executive of Galenica Pharmaceuticals.

The Biotechnology Industry Organization (BIO) represents more than 1,100 biotechnology companies, academic institutions, biotechnology centres and related organisations across the US and in more than 30 other nations.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

You may also like

Finance

SuperGen to acquire Astex Therapeutics

Creating an international developer of cancer drugs
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical

Moderna named a top employer by Science for eleventh consecutive year

Moderna was recognised for its commitment to continuous innovation and a culture that reflects the values of its employees.
Pharmaceutical

Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Pharmaceutical

Takeda and Innovent Biologics partner to advance next-gen oncology medicines

Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Subscribe now